帕罗西汀联合小剂量碳酸锂治疗抑郁症对照研究

目的 探讨帕罗西汀联合小剂量碳酸锂治疗抑郁症的临床疗效及安全性. 方法 将80例抑郁症患者随机分为两组,每组40例,实验组口服帕罗西汀联合小剂量碳酸锂治疗,对照组单用帕罗西汀治疗.观察8周.于治疗前及治疗4周、8周末采用汉密顿抑郁量表评定临床疗效,副反应量表评定不良反应. 结果 治疗后两组汉密顿抑郁量表评分均较治疗前显著下降（P＜0.01）;治疗8周末,实验组显效率92.5%,对照组为90.0%,两组无显著性差异（P＞0.05）.治疗后两组不良反应均较轻微,但实验组口干、便秘、视物模糊、全身不适、失眠等不良反应发生率均显著低于对照组（P＜0.05或0.01）. 结论 帕罗西汀联合小剂量碳酸锂治疗抑郁症疗效显著,与单用帕罗西汀总体疗效相当,但不良反应发生率更低,安全性更高,依从性更好.

A control study of paroxetine plus small dose lithium carbonate in the treatment of depression

Objective To explore the clinical efficacy and safety of paroxetine plus small dose lithium carbonate in the treatment of depression. Methods Eighty depression patients were randomly divided into two groups of 40 ones each, experimental group took orally paroxetine plus small dose lithium carbonate and control group did paroxetine only for 8 weeks. Clinical efficacies were assessed with the Hamilton Depression Scale （HAMD） and adverse reactions with the Treatment Emergent Symptom Scale （TESS） before treatment and at the end of the 4th and 8th week. Results After treatment, scores of the HAMD of both groups lowered more significantly compared with pretreatment （P〈0. 01）; at the end of the 8th week, obvious effective rates were respectively 92. 5% in the experimental and 90. 0% in the control group, which showed no significant difference （P〉0.05）. Adverse reactions of both groups were mild, but incidences of dry mouth, constipation, blurred vision, general malaise, insomnia etc. were significantly lower in the experimental than in the control group （P〈0.05 or 0.01）. Conclusion Paroxetine combined with small dose lithium carbonate has a significant curative effect equivalent to paroxetine only in depression, but lower incidences of adverse reactions, higher safety, better compliance and lower treatment costs.